Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Blood. 2020 Oct 22;136(17):1983-1988. doi: 10.1182/blood.2020006113.

Florian Perner^{1

2}, Jayant Y Gadrey^{1

2}, Yijun Xiong^{1

2}, Charles Hatton^{1

2}, Benjamin K Eschle^{1

2}, Andreas Weiss³, Frédéric Stauffer³, Christoph Gaul³, Ralph Tiedt³, Jennifer A Perry^{1

2}, Scott A Armstrong^{1

2}, Andrei V Krivtsov^{1

2}

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.
² Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA; and.
³ Novartis Institutes for Biomedical Research, Basel, Switzerland.

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.